Table 1 Clinical characteristics of the Cancer Genome Atlas data
From: Identification of miR-143-3p as a diagnostic biomarker in gastric cancer
Cohorts | Analysis set, n (%) | Validation set, n (%) |
|---|---|---|
Characteristic | Gastric cancer (n = 272) | Gastric cancer (n = 117) |
Gender, n (%) | Â | Â |
Male | 168 (61.8) | 88 (75.2) |
Female | 104 (38.2) | 29 (24.8) |
Age (years) | Â | Â |
Mean ± SD | 65.33 ± 10.50 | 65.08 ± 10.64 |
NA | 5 | – |
Pathologic stage, n (%) | Â | Â |
Stage I | 35 (12.9) | 16 (13.7) |
Stage II | 102 (37.5) | 22 (18.8) |
Stage III | 113 (41.5) | 61 (52.1) |
Stage IV | 17 (6.3) | 15 (12.8) |
NA | 5 (1.8) | 3 (2.6) |
Primary tumor (T), n (%) | Â | Â |
T1 | 11 (4.0) | 10 (8.6) |
T2 | 63 (23.2) | 15 (12.8) |
T3 | 119 (43.8) | 62 (53.0) |
T4 | 79 (29.0) | 30 (25.6) |
Regional lymph node (N), n (%) | Â | Â |
N0 | 95 (34.9) | 26 (22.2) |
N1 | 68 (25.0) | 32 (27.4) |
N2 | 49 (18.0) | 30 (25.6) |
N3 | 56 (20.6) | 26 (22.2) |
NX | 3 (1.1) | 3 (2.6) |
NA | 1 (0.4) | – |
Distant metastasis (M), n (%) | Â | Â |
M0 | 245 (90.1) | 102 (87.2) |
M1 | 13 (4.8) | 10 (8.5) |
MX | 14 (5.1) | 5 (4.3) |